PowerShares Dynamic Pharmaceuticals ETF
Latest PowerShares Dynamic Pharmaceuticals ETF News and Updates
Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders
Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.
What Are Generic Drugs and Why Are They Important?
TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]
Understanding Allergan’s Valuation after the 1Q17 Results
On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.
A Look into Merck’s Immunology and Oncology Portfolio
In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.
Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17
In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.
How Amgen’s Nephrology Drugs Are Positioned after 2Q17?
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst
Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.
Maverick Capital Increases Stake in Novartis
Maverick Capital increased its position in Novartis (NVS) by more than $22 million in stock. It represented 0.75% of the fund’s total portfolio in 4Q14.
A Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.
An Easier Way to Understand the Pharma Industry
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
Overview: New York Fed’s advice to revive Puerto Rico’s economy
In 2011, led by Dr. William Dudley, the New York Fed had commissioned a report on the major economic issues facing the island of Puerto Rico.
How Bausch Health’s Financials Look in November
Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.
A Look at Merck’s Diabetes and Women’s Health Business
Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.
How Did Pharmaceutical ETFs Perform in Q3 2018?
The Healthcare Select Sector SPDR ETF’s (XLV) price has increased ~14.6% in the third quarter, and its year-to-date returns increased ~15.5% on October 2.
Allergan’s SpotLyte and Lumivive System
SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
What’s Eli Lilly’s Valuation as of September 27?
Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue.
Vermont Legalizes Recreational Marijuana on January 22, 2018
On January 22, Vermont decriminalized the possession of marijuana for adults 21 and older. Vermont became the ninth state to legalize marijuana for recreational purposes.
Behind Valeant’s Branded Drugs: Other 3Q17 Performances
In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.
How Analysts Rated Jazz Pharmaceuticals in December
In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.
Valeant Pharmaceuticals’ Siliq Approved for Plaque Psoriasis
In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals’ (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.
How Pfizer’s Premarin and Other Legacy Established Products Performed
In 3Q17, Pfizer’s (PFE) Premarin generated revenues of $238 million, a ~2% decline on a YoY basis and a 3% decline on a quarter-over-quarter basis.
Keytruda: Driving Merck’s Growth
For 3Q17, Keytruda reported revenues of ~$1.1 billion, a 194% growth compared to revenues of $356 million in 3Q16.
Behind Eli Lilly’s Alimta and Other Oncology Products in 3Q17
In 3Q17, Eli Lilly’s overall revenues from oncology products fell due to lower sales of Alimta, Erbitux, and Portrazza, offset by a rise in Cyramza sales.
Merck’s Immunology and Oncology Drugs, Post-3Q17
Immunology drug revenue In 3Q17, Remicade generated revenue of $214 million, a ~31% fall YoY (year-over-year) and 3% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Remicade reported revenue of $651 million, which reflected a ~35% fall YoY. Foreign exchange had a 3% favorable effect towards 3Q17 Remicade revenue. In 3Q17, Simponi reported revenue of […]
What Led to the Rise in the US Trade Deficit in September?
The latest report was released on November 3 and indicated that the goods and services deficit was $43.5 billion in September, or $0.7 billion higher than in August.
Bristol-Myers Squibb’s Cardiovascular Portfolio
Bristol-Myers Squibb’s (BMY) cardiovascular portfolio includes the blockbuster drug Eliquis, developed in alliance with Pfizer (PFE).
How Merck’s Diabetes Portfolio Performed in 2Q17
Merck’s (MRK) diabetes portfolio includes drugs used for controlling the blood sugar levels for patients with diabetes.
Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018
In August 2017, JAZZ’s Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.
Eli Lilly & Co.’s Recent Developments after Its 2Q17 Earnings
On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.
Performance of Eli Lilly’s Endocrine Franchise in 2Q17
Forteo is used for the treatment of osteoporosis. Forteo’s sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16.
How Pfizer’s Enbrel and Xeljanz Are Positioned after 2Q17
In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.
A Post-2Q17 Look at Pfizer’s Internal Medicines
In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.
Bristol-Myers Squibb’s Immunoscience Products in 2Q17
Orencia revenues rose to $650.0 million in 2Q17, a 10.0% rise compared to $593 million in 2Q16.
What Jazz Pharmaceuticals Expects for Vyxeos
If Vyxeos manages to penetrate a sizeable portion of the target market, it may have a favorable impact on Jazz Pharmaceuticals stock.
How Allergan’s US Specialized Therapeutics Segment Performed in 2Q17
The US Specialized Therapeutics segment reported revenues of $1.7 billion in 2Q17, a 15.2% increase as compared to $1.5 billion during 2Q16.
Behind Xyrem’s Solid Demand Trends in 2017
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem reported revenues of ~$298 million, which represented a YoY (year-over-year) growth of ~6% and sequential growth of ~9%.
Celgene’s Abraxane Continued Steady Growth in 2Q17
In 2Q17, Celgene’s (CELG) Abraxane generated revenues of around $254 million, which reflected ~2% growth on a year-over-year basis.
Dupixent Could Substantially Drive Regeneron’s Growth
In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.
Examining Bristol-Myers Squibb’s Oncology Portfolio’s 2Q17
The key products in Bristol-Myers Squibb’s (BMY) oncology portfolio include Empliciti, Opdivo, Sprycel, and Yervoy. Let’s take a closer look at these drugs and their performances.
Eli Lilly in 2Q17: Humulin and Endocrine Products
Eli Lilly’’s (LLY) Human Pharmaceuticals segment reported a rise of ~11.0% to ~$5.0 billion for 2Q17 compared to ~$4.6 billion for 2Q16.
Behind Pfizer’s Legacy Established Products Performance in 2017
In 2016, Pfizer’s (PFE) Lipitor reported revenues of ~$1.8 billion, which represented a ~5% YoY (year-over-year) fall.
Behind Allergan’s Business Segments and Revenues
Allergan’s (AGN) business has undergone several changes over the past few years due to acquisitions and divestitures.
How Bristol-Myers Squibb Stock Has Performed in 2Q17
A look at Bristol-Myers Squibb Headquartered in New York City, Bristol-Myers Squibb (BMY) is an American pharmaceutical company that develops innovative medicines in various therapeutic areas, including cardiovascular, neuroscience, immunoscience, oncology, and virology. Stock price performance While Bristol-Myers Squibb’s stock price has risen ~3.8% in 2Q17, it had fallen ~5.4% year-to-date as of July 7, […]
How Did Keytruda Perform in 1Q17?
Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.
A Look at Pfizer’s Revenue for 1Q17
Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.
How Johnson & Johnson’s Valuation Changed Post-1Q17
Heavyweight pharmaceutical company Johnson & Johnson (JNJ) reported earnings per share (or EPS) of $1.83 on revenue of $17.8 billion in 1Q17.
Performance of Merck’s Diabetes Portfolio in 1Q17
Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.
Bristol-Myers Squibb’s 1Q17 Estimates: Virology Segment
The Virology segment is Bristol-Myers Squibb’s (BMY) second-largest revenue contributor. The segment contributes ~25% of the company’s total revenue.
Johnson & Johnson’s 1Q17 Segment-by-Segment Performance
JNJ’s overall business is classified into three segments: Pharmaceuticals, Consumer, and Medical Devices. At constant exchange rates, the company reported growth across all of its segments.
Johnson & Johnson’s 1Q17 Estimates: Pharmaceuticals Segment
Johnson & Johnson’s (JNJ) Pharmaceuticals segment includes immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics.
Analyzing the Performance of Abbott Laboratories in 1Q17
Abbott Laboratories’ stock price rose ~7.1% in 1Q17. On April 7, 2017, the stock’s price had risen 13.7% year-to-date (or YTD).
Bausch & Lomb Continues to be Key Growth Driver for Valeant
Bausch & Lomb projections Valeant Pharmaceuticals expects its Bausch & Lomb/International segment to grow at a CAGR (compound average growth rate) of 4%–6% between 2017 and 2020. In 2017, the company expects the segment to grow 5%–7% after adjusting for foreign exchange fluctuations and the impact of impending patent expiries. In 2017, the segment is also expected […]
New Product Launches May Boost Valeant’s Dermatology Revenue
New product launches Despite upcoming patent expirations for drugs Elidel, Solodyn, and Acanya in 2018, and Zyclara in 2019, Valeant Pharmaceuticals (VRX) expects to boost its dermatology revenue after 2018 through new product launches. On December 12, 2016, the company hired Bill Humpries as executive vice president and head of the dermatology team. The change […]
Key Investor Insights into Eli Lilly’s Recent Developments
Overall, Eli Lilly’s (LLY) segment-wise performance in 3Q16 was positive for both its Human Pharmaceuticals and Animal Health segments.
Why Generic Drugs Will Play a Key Role in the Future
Although generic drugs are the same as branded drugs in terms of the medicinal effect, their prices are extremely low compared to the branded products.
Understanding Merck’s Business Segments and Their Revenue Trends
Merck & Co. has separated its business operations into two business segments: the Global Human Health business and the Animal Health business.
Population Dynamics for Gilead’s HCV Products
There are six distinct genotypes of HCV (hepatitis C virus). If we know the genotype, recommending the treatment and duration becomes easier.
Pall Acquisition Gave Birth to Danaher’s Filtration Business
Danaher’s filtration business came into existence through the acquisition of Pall in 2015.
How Are Eli Lilly’s Business Segments Performing?
Eli Lilly and Co.’s (LLY) overall business is classified into two business segments—Human Pharmaceuticals and Animal Health.
Bristol-Myers Squibb’s 2Q16 Estimates: Expect Growth!
Bristol-Myers Squibb (BMY) is expected to report revenue growth of over 11% to $4.7 billion in its 2Q16 results on July 28, 2016.
How Has Manufacturing Its Own Active Pharmaceutical Ingredients Helped Mylan?
Mylan is one of largest API (active pharmaceutical ingredient) manufacturers in the world, with nine API and intermediate manufacturing facilities.
Mylan’s Business Model: A Key Investor Rundown
In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.
The PowerShares Dynamic Pharmaceuticals ETF: Holdings Breakdown
As of November 2015, the PowerShares Dynamic Pharmaceuticals ETF (PJP) was one of the top-performing smart beta ETFs in the market.
Comparing the PowerShares Dynamic Biotechnology & Genome Portfolio with PJP
PJP saw healthy growth in its volume and fund inflows compared to PBE as of November. Volumes traded per day grew in 2014 for PJP and PBE but fell in 2015.
Big pharma invests big money in research and development
Research and development is likely the most vital part of big pharma. Out of every 10,000 drugs developed, barely 10 reach the market.